• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dual inhibition of EGFR and PI3K with a single drug.

作者信息

Katerji Meghri, Rubin Maxine R, Brognard John

机构信息

Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, USA.

出版信息

Nat Cancer. 2024 Aug;5(8):1131-1133. doi: 10.1038/s43018-024-00806-0.

DOI:10.1038/s43018-024-00806-0
PMID:39152227
Abstract
摘要

相似文献

1
Dual inhibition of EGFR and PI3K with a single drug.用单一药物对表皮生长因子受体（EGFR）和磷脂酰肌醇-3-激酶（PI3K）进行双重抑制。
Nat Cancer. 2024 Aug;5(8):1131-1133. doi: 10.1038/s43018-024-00806-0.
2
EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.表皮生长因子受体和 PI3K 信号通路作为转移性胃腺癌患者循环肿瘤细胞的有前途的靶点。
Int J Mol Sci. 2024 May 20;25(10):5565. doi: 10.3390/ijms25105565.
3
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance.一种首创的 EGFR 和 PI3K 选择性抑制剂为靶向适应性耐药提供了一种单一分子的方法。
Nat Cancer. 2024 Aug;5(8):1250-1266. doi: 10.1038/s43018-024-00781-6. Epub 2024 Jul 11.
4
ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells.ABCG2 介导癌细胞对双重 EGFR 和 PI3K 抑制剂 MTX-211 的耐药性。
Int J Mol Sci. 2024 May 9;25(10):5160. doi: 10.3390/ijms25105160.
5
Ursodeoxycholic acid shows antineoplastic effects in bile duct cancer cells via apoptosis induction; p53 activation; and EGFR-ERK, COX-2, and PI3K-AKT pathway inhibition.熊去氧胆酸通过诱导细胞凋亡、激活 p53 以及抑制 EGFR-ERK、COX-2 和 PI3K-AKT 通路，显示出对胆管癌细胞的抗肿瘤作用。
Mol Biol Rep. 2021 Sep;48(9):6231-6240. doi: 10.1007/s11033-021-06331-y. Epub 2021 Aug 14.
6
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.抑制 PI3K/AKT 通路增强了表皮生长因子受体激酶抑制剂在三阴性乳腺癌细胞中的细胞毒性。
J Cell Mol Med. 2013 May;17(5):648-56. doi: 10.1111/jcmm.12046. Epub 2013 Apr 20.
7
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.HER激酶激活赋予对MET致癌基因成瘾的胃癌细胞中MET酪氨酸激酶抑制的抗性。
Mol Cancer Ther. 2008 Nov;7(11):3499-508. doi: 10.1158/1535-7163.MCT-08-0374. Epub 2008 Oct 30.
8
Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC.设计、合成及双靶点 EGFR-PI3Kα 抑制剂的生物评价用于潜在治疗 NSCLC。
Bioorg Chem. 2024 Oct;151:107714. doi: 10.1016/j.bioorg.2024.107714. Epub 2024 Aug 10.
9
Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.同时针对 HPV 阳性头颈部鳞状细胞癌中的 ErbB 家族激酶和 PI3K。
Oral Oncol. 2022 Aug;131:105939. doi: 10.1016/j.oraloncology.2022.105939. Epub 2022 Jun 3.
10
30 years of PI3K: an interview with Bart Vanhaesebroeck.PI3K的30年：对巴特·范海瑟布罗克的采访
Future Oncol. 2024;20(20):1381-1384. doi: 10.2217/fon-2024-0215. Epub 2024 May 28.

本文引用的文献

1
Cetuximab chemotherapy resistance: Insight into the homeostatic evolution of head and neck cancer (Review).西妥昔单抗化疗耐药：对头颈部癌的体内进化的深入了解（综述）。
Oncol Rep. 2024 Jun;51(6). doi: 10.3892/or.2024.8739. Epub 2024 Apr 19.
2
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.Alpelisib 联合西妥昔单抗治疗复发性或转移性头颈部鳞状细胞癌的 1b/2 期研究。
Target Oncol. 2023 Nov;18(6):853-868. doi: 10.1007/s11523-023-00997-z. Epub 2023 Oct 25.
3
Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer.
非小细胞肺癌中对表皮生长因子受体靶向治疗获得性耐药和耐受性的机制
Cancers (Basel). 2023 Jan 13;15(2):504. doi: 10.3390/cancers15020504.
4
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.针对 EGFR 酪氨酸激酶抑制剂耐药的 EGFR 突变型非小细胞肺癌患者的治疗策略和结局：关注新型疗法。
Lung Cancer. 2022 Aug;170:41-51. doi: 10.1016/j.lungcan.2022.05.011. Epub 2022 May 21.
5
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.与α-选择性PI3K抑制剂阿培利司治疗乳腺癌相关的高血糖管理策略
Cancers (Basel). 2022 Mar 22;14(7):1598. doi: 10.3390/cancers14071598.
6
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.一项评估选择性 PI3K 抑制剂 copanlisib 联合西妥昔单抗治疗复发性和/或转移性头颈部鳞状细胞癌患者的 I 期临床试验。
Invest New Drugs. 2021 Dec;39(6):1641-1648. doi: 10.1007/s10637-021-01152-z. Epub 2021 Jul 28.
7
Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.库潘尼西治疗复发滤泡性淋巴瘤：临床应用与经验
Cancer Manag Res. 2021 Jan 25;13:677-692. doi: 10.2147/CMAR.S201024. eCollection 2021.
8
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.考比替尼与西妥昔单抗联合使用可改善西妥昔单抗耐药的头颈癌患者来源异种移植瘤的肿瘤反应。
Oncotarget. 2020 Oct 13;11(41):3688-3697. doi: 10.18632/oncotarget.27763.
9
EGFR in head and neck squamous cell carcinoma: exploring possibilities of novel drug combinations.头颈部鳞状细胞癌中的表皮生长因子受体：探索新型药物联合使用的可能性
Ann Transl Med. 2020 Jul;8(13):813. doi: 10.21037/atm.2020.04.07.
10
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.AXL通过激活头颈部和食管鳞状细胞癌中的EGFR/PKC/mTOR轴介导对PI3Kα抑制的抗性。
Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.